Tobias Financial Advisors Inc. Purchases 412 Shares of Johnson & Johnson (NYSE:JNJ)

Tobias Financial Advisors Inc. raised its position in Johnson & Johnson (NYSE:JNJ) by 9.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,941 shares of the company’s stock after acquiring an additional 412 shares during the period. Tobias Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $715,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in JNJ. Canada Pension Plan Investment Board raised its position in shares of Johnson & Johnson by 6.7% in the fourth quarter. Canada Pension Plan Investment Board now owns 4,528,010 shares of the company’s stock valued at $654,841,000 after purchasing an additional 283,544 shares during the period. GKV Capital Management Co. Inc. bought a new stake in Johnson & Johnson during the 4th quarter valued at $506,000. First Commonwealth Financial Corp PA lifted its position in shares of Johnson & Johnson by 13.7% during the fourth quarter. First Commonwealth Financial Corp PA now owns 9,922 shares of the company’s stock worth $1,435,000 after acquiring an additional 1,198 shares in the last quarter. Capital Square LLC boosted its holdings in shares of Johnson & Johnson by 16.9% in the fourth quarter. Capital Square LLC now owns 5,868 shares of the company’s stock worth $862,000 after acquiring an additional 848 shares during the period. Finally, MSH Capital Advisors LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $2,152,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.2 %

JNJ stock opened at $153.95 on Thursday. The company has a market capitalization of $371.00 billion, a PE ratio of 23.15, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company’s 50 day moving average price is $159.40 and its two-hundred day moving average price is $155.10.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.38%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Analysts Set New Price Targets

Several research analysts have commented on JNJ shares. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday. Bank of America cut their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company reduced their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Morgan Stanley increased their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Nine analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $171.78.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.